KMD3B loss or chemical inhibition directly promotes MLL/KMT2A extrachromosomal amplifications and rearrangements, which are often associated with KMD3B LOH in AML (Gray et al. 2023). The gene discussed is KMT2A; the disease is acute myeloid leukemia.